Atrial Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Biovalve Implantation
Completed
- Conditions
- Atrial FibrillationStrokeAortic StenosisTransient Ischemic AttackBleeding
- Registration Number
- NCT02626871
- Lead Sponsor
- University of Turku
- Brief Summary
The primary purpose of the FIN-bioAVR registry is to assess the incidence of AF, strokes and major bleeding events in patients undergoing aortic valve replacement. This retrospective multicenter registry will include 850 patients with aortic valve replacement using bioprosthesis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 850
Inclusion Criteria
- patients undergoing aortic valve bioprosthesis implantation
Exclusion Criteria
- mechanical heart valves in any position
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mortality 10 years major bleeding 10 years Stroke 10 years atrial fibrillation 10 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link aortic biovalve implantation to atrial fibrillation development in patients with aortic stenosis?
How does aortic valve replacement with bioprosthesis compare to standard-of-care treatments in preventing stroke and bleeding events in elderly patients?
What biomarkers are associated with increased risk of postoperative atrial fibrillation and stroke in aortic valve replacement patients?
What are the most effective management strategies for anticoagulation-related bleeding in patients with aortic biovalve implants and atrial fibrillation?
What combination therapies or alternative interventions are being explored to reduce stroke and bleeding risks in aortic valve replacement patients with comorbid conditions?
Trial Locations
- Locations (1)
Turku University Hospital
🇫🇮Turku, Finland
Turku University Hospital🇫🇮Turku, Finland